Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 8/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268597 | 1.00 | NAMPT (0.41) | NAMPTRORCTACR1DPP4ALOX5AP | |
| SCHEMBL26696288 | 0.91 | NAMPT (0.41) | NAMPTRORCTACR1DPP4ALOX5AP | |
| SCHEMBL26610838 | 0.86 | EPHX1 (0.39) | TACR1DPP4CHRM2CHRM4CHRM3 | |
| SCHEMBL26610840 | 0.86 | EPHX1 (0.39) | TACR1DPP4CHRM2CHRM4CHRM3 | |
| SCHEMBL26726272 | 0.83 | NAMPT (0.39) | NAMPTRORCTACR1GPR119TGFBR1 | |
| SCHEMBL26705566 | 0.83 | NAMPT (0.39) | NAMPTRORCTACR1GPR119TGFBR1 | |
| SCHEMBL30662846 | 0.83 | NAMPT (0.39) | NAMPTRORCTACR1GPR119TGFBR1 | |
| SCHEMBL27152357 | 0.83 | NAMPT (0.39) | NAMPTRORCTACR1GPR119TGFBR1 | |
| SCHEMBL26604552 | 0.83 | USP30 (0.44) | NAMPTRORCTACR1NR1H2GPR119 | |
| SCHEMBL26604456 | 0.82 | NAMPT (0.43) | NAMPTRORCTACR1NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2025090811-A1 | METHODS OF MODULATING CELL PROLIFERATION | KUMQUAT BIOSCIENCES INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4511128-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12195465-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240208975-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208975-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | NAMPT 1597/4885RORC 1682/4885TACR1 4084/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | NAMPT 1597/4885RORC 1682/4885TACR1 4084/4885 |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | NAMPT 4853/4885RORC 1497/4885TACR1 2174/4885 |
| US-12195465-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | NAMPT 1597/4885RORC 1682/4885TACR1 4084/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | NAMPT 1597/4885RORC 1682/4885TACR1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.